Description: Each Pen of CinnoPar® containing 600µg (250 µg /1ml) Teriparatide for subcutaneous injection, produced under EU GMP license.
Indication: Glucocorticoid-induced osteoporosis, osteoporosis in men and osteoporosis in postmenopausal women who are at high risk for fractures.
Protein type: Hormone
Mechanism of action: Stimulates the bone formation by direct effects on bone-forming cells (osteoblasts), increasing intestinal absorption of calcium and excretion of phosphate.
Description: Adalimumab is a human monoclonal antibody against TNF-alpha. It is produced by recombinant DNA technology using a mammalian cell expression system.
Indication: For treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, juvenile idiopathic arthritis, psoriasis, pediatric plaque psoriasis, hidradenitis suppurativa, pediatric crohn’s disease, Uveitis.
Protein type: Monoclonal antibody (mAb)
Description: This medicine is produced as prefilled syringes containing solution form with two different dosages: 25 mg and 50 mg
Indication: Rheumatoid Arthritis, Plaque Psoriasis, Psoriasis Arthritis, Spondyloarthritis, Ankylosing Spondylitis and Juvenile Idiopathic.
Protein type: Fusion proteins
Mechanism of action: Etanercept binds specifically to tumor necrosis factor (TNF) and thereby modulates biological processes that are induced or regulated by TNF.